GenSpera announces first patient dosed cancer therapy & Research Center in current G-202 phase I study

Current article ratings:
Patients / public:5 (1 votes)healthcare Prof:
GenSpera, Inc. (OTCBB: GNSZ) known, the first patient in the ongoing phase dose was I clinical trial with its chemotherapeutic agent, G-202, the cancer therapy & Research Center (CTRC) at the University of Texas Health Science Center in San Antonio in San Antonio Texas. CTRC is the University of Wisconsin Carbone Cancer Center, in Madison, Wisconsin, and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in Baltimore, Maryland, as the third Center participate in the phase I security study G-202 in patients whose Krebserkrankungen have progressed after treatment with other chemotherapies.

"I'm happy to have the opportunity, my patients offer a further new therapy for the treatment of cancer,", said Devalingam N., m.d. PhD., principal investigator of the study of the CTRC. "Much has shown promising G 202 in pre-clinical tests so I am confident that it will show good clinical efficacy in my patients."

"We are delighted that could is now treating patients," commented Craig Dionne, PhD., GenSpera CEO and President. "We have been carefully selected to achieve their experience and a cross-section of the patients, our clinical hospitals for both and are pleased to bring this third Center of excellence in our study."

About the study

Up to 30 patients with cancers for registering the G-202-phase I trial have progressed after treatment with other anti-cancer agents. The primary endpoints of the open-label dose escalation study are to determine, the safety, tolerability, and pharmacokinetics of the drug, although the design collection of efficacy data as well as possible. The trial has Register also providing further to eighteen patients at an advanced stage IB cohort at the maximum tolerated dose of the drug.

Source:
GenSpera, Inc.